Who Should Not Take DHEA: Contraindications and Risk Groups

DHEA is often marketed abroad as a gentle "youth hormone" sold next to vitamins. In reality it is a steroid precursor that the body can turn into testosterone and oestrogens, and for a sizeable share of people it is simply a bad idea. Our editorial team has set out who should stay away from it, why, and what the legal position looks like in the UK.

What DHEA is and why it is not a harmless supplement

Dehydroepiandrosterone (DHEA) is produced mainly by the adrenal glands and circulates largely as its sulphate, DHEA-S. Levels peak in the mid-twenties and fall steadily with age, which is the observation behind decades of anti-ageing marketing. The decline itself, however, does not prove that topping the hormone up is beneficial.

Once swallowed, DHEA enters the same enzymatic pathways that the body uses to make sex hormones. In tissues such as fat, skin and the prostate it can be converted into androstenedione, testosterone, dihydrotestosterone and, via aromatase, into oestradiol and oestrone. The end product depends on sex, age, body composition and enzyme activity, so the effect is hard to predict for any individual.

That unpredictability is the core of the problem. In men a large part of the extra DHEA may end up as oestrogen; in women it tends to raise testosterone noticeably. A product that looks like a mild supplement on paper therefore behaves more like a weak, poorly controlled hormone therapy.

Clinical evidence for benefits in healthy people is thin. A two-year randomised trial in older men and women published in the New England Journal of Medicine found no meaningful improvements in body composition, physical performance or quality of life. Proven medical uses are narrow, which makes the list of people who should avoid it all the more important.

Hormone-sensitive conditions: the clearest no

The strongest contraindication applies to anyone with a current or past hormone-dependent cancer. That includes breast, ovarian, endometrial and prostate cancer. Because DHEA can raise both androgens and oestrogens, it may in theory feed tumour cells whose growth is driven by those hormones, and no oncologist would accept that risk outside a trial.

The same caution extends to people at high genetic risk, such as carriers of BRCA variants, and to men with raised PSA or untreated benign prostatic enlargement. Even where cancer has not been diagnosed, adding a hormone precursor can complicate screening and muddy the interpretation of blood results.

Conditions marked by androgen excess are another clear group. Women with polycystic ovary syndrome (PCOS), hirsutism or androgenic acne often already have high androgen levels, and DHEA can make symptoms such as unwanted hair growth, oily skin and irregular cycles worse.

Endometriosis, fibroids and other oestrogen-sensitive gynaecological conditions also argue against self-medication. The table below summarises the main groups our editors consider unsuitable for DHEA without specialist supervision.

Women, pregnancy and young people

Women are more sensitive to the androgenic effects of DHEA than men. Even moderate amounts can raise circulating testosterone above the normal female range, and some changes, such as a deeper voice or hair loss in a male pattern, may not reverse completely after stopping.

The Endocrine Society's guideline on androgen therapy in women advises against routine use of DHEA, citing inconsistent benefits and a lack of long-term safety data. The one area where DHEA has some licensed use is a vaginal prasterone preparation for postmenopausal vulvovaginal atrophy, which is a local, specialist-prescribed product rather than an oral supplement.

Pregnant and breastfeeding women should not take it. Sex hormones influence foetal development, and there are no safety data supporting exposure. People undergoing fertility treatment sometimes read about DHEA for "poor ovarian response"; that question belongs strictly to the fertility clinic, not to an online purchase.

Teenagers form the final group in this section. During puberty the hormonal axis is still maturing, and external steroids, including precursors, can disturb growth plate closure, skin, mood and the timing of sexual development. Young athletes looking for an edge should be steered towards training, sleep and food instead.

Medicines, mental health and metabolic risks

DHEA can interact with prescribed medicines in several ways. It may blunt or amplify hormone therapies, from contraceptive pills and HRT to anti-oestrogen treatments such as tamoxifen and aromatase inhibitors. Anyone on these drugs needs to discuss DHEA with the prescriber before taking a single tablet.

Readers frequently ask us about Methyldrostanolone.

Psychiatric history matters as well. Case reports have linked DHEA to episodes of mania and irritability, especially in people with bipolar disorder. Those taking antidepressants, mood stabilisers or antipsychotics should be particularly careful, as should anyone who reacts strongly to hormonal changes.

Some studies in women have recorded a fall in HDL ("good") cholesterol on oral DHEA, and androgens can affect insulin sensitivity. People with established heart disease, poorly controlled diabetes or significant liver disease, which alters steroid metabolism, are therefore poor candidates.

Before considering DHEA for any reason, a sensible checklist includes:

• a review of all prescribed and over-the-counter medicines with a pharmacist or GP;
• baseline blood tests if a doctor agrees there is a reason to check hormones, such as DHEA-S, testosterone and lipids;
• an honest look at personal and family history of cancer and mental illness;
• a clear goal, because "general wellbeing" is not a medical indication.

Athletes, the law and product quality

For anyone in tested sport the answer is simple: DHEA (prasterone) is listed by the World Anti-Doping Agency among anabolic agents and is prohibited both in and out of competition. UK Anti-Doping applies the same list, and a positive test carries the same consequences as any other anabolic steroid.

In the UK, DHEA is also controlled under the Misuse of Drugs Act as a Class C substance in the anabolic steroid group. It cannot be lawfully sold as a food supplement, and supplying it without authorisation is an offence. Products bought from overseas websites therefore sit outside the safeguards that apply to medicines.

Quality is a separate worry. Independent analyses of hormone-type supplements have repeatedly found products that contain less or more than stated, or that include undeclared steroids. For a substance where small differences in dose already change the outcome, that variability adds avoidable risk.

If a doctor does suspect adrenal insufficiency or another endocrine disorder, investigation and treatment follow NHS pathways. In primary adrenal insufficiency, for example, guidelines discuss DHEA only as a possible add-on for selected women with persistent symptoms, never as the first step.

Conclusions of the editorial team

DHEA is a steroid precursor whose fate in the body is difficult to predict, and its benefits in healthy adults remain unproven. That alone should lower expectations, regardless of what overseas packaging promises.

People with hormone-sensitive cancers or a strong family risk, women with PCOS or other androgen-excess conditions, pregnant and breastfeeding women, teenagers and those with bipolar disorder form the clearest groups who should not take it.

Competitive athletes face an outright ban, and in the UK the substance is legally controlled. Anyone with symptoms that seem hormonal deserves proper testing rather than guesswork with a precursor of uncertain quality.

For further reading, we suggest our articles on how to interpret a male hormone panel, on what the WADA Prohibited List covers, and on natural ways to support healthy testosterone levels.

References

1. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355(16):1647–1659.
2. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med. 1999;341(14):1013–1020.
3. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489–3510.
4. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(2):364–389.
5. Brown GA, Vukovich MD, Sharp RL, et al. Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J Appl Physiol. 1999;87(6):2274–2283.
6. World Anti-Doping Agency. The Prohibited List. Montreal: WADA; updated annually.